Suppliers and packagers for relenza

relenza

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Glaxosmithkline	RELENZA	zanamivir	POWDER;INHALATION	021036	NDA	GlaxoSmithKline LLC	0173-0681-01	5 PACKAGE in 1 CARTON (0173-0681-01) / 4 POWDER in 1 PACKAGE	1999-09-22
Glaxosmithkline	RELENZA	zanamivir	POWDER;INHALATION	021036	NDA	GlaxoSmithKline LLC	0173-0681-22	5 PACKAGE in 1 CARTON (0173-0681-22) / 4 POWDER in 1 PACKAGE	1999-09-22

Relenza Drug Supply Chain Analysis

Last updated: February 19, 2026

This report identifies key suppliers and manufacturing locations critical to the production of Relenza (Zanamivir), a neuraminidase inhibitor antiviral medication. The analysis focuses on active pharmaceutical ingredient (API) manufacturing and formulation, as well as potential risks and redundancies within the supply chain.

What is Relenza and its Active Pharmaceutical Ingredient?

Relenza is a prescription medication used for the treatment and prevention of influenza A and B infections. Its active pharmaceutical ingredient (API) is Zanamivir. Zanamivir is a potent and selective inhibitor of the viral neuraminidase enzyme [1]. This enzyme is crucial for the release of newly formed virus particles from infected host cells and for the spread of the virus [2]. By inhibiting neuraminidase, Zanamivir prevents the proliferation of influenza viruses.

Zanamivir is administered via inhalation using a special device called the Diskhaler [3]. This delivery method targets the drug directly to the respiratory tract, where the influenza virus replicates. The mechanism of action involves Zanamivir binding to the active site of the neuraminidase enzyme, preventing it from cleaving sialic acid residues on the surface of host cells and viral particles. This blockade inhibits the shedding of new virions and viral spread [2].

The development of Zanamivir was a significant advancement in antiviral therapy, offering an alternative to treatments targeting other viral components or processes. Its efficacy is demonstrated in reducing the duration and severity of influenza symptoms when administered early in the course of illness [1, 3].

Who Manufactures Zanamivir API?

The primary manufacturer and supplier of Zanamivir API is GlaxoSmithKline (GSK). GSK, a multinational pharmaceutical company headquartered in the United Kingdom, holds the patent and controls the manufacturing process for Zanamivir [4].

GSK's manufacturing operations for Zanamivir API are concentrated at specific, highly controlled facilities. While the exact locations are proprietary and subject to regulatory oversight, major GSK manufacturing sites with capabilities for complex API synthesis are likely involved. These facilities adhere to stringent Good Manufacturing Practices (GMP) standards to ensure the quality, purity, and consistency of the API [5].

The synthesis of Zanamivir involves a multi-step chemical process. Key starting materials and intermediates are sourced from specialized chemical manufacturers, many of whom operate under contract with GSK. These upstream suppliers are vetted for their quality control and adherence to regulatory requirements [6].

As the originator of Zanamivir, GSK maintains exclusive rights and direct oversight of its API production. This vertical integration minimizes reliance on external API manufacturers, thereby enhancing supply chain security. However, it also means that any disruption at GSK's designated API manufacturing sites could have a direct impact on Zanamivir availability.

A potential concern regarding the Zanamivir API supply chain is the limited number of primary manufacturers. While generic versions of Zanamivir are not currently widely available due to patent protection and market exclusivity for GSK, the long-term production landscape could shift upon patent expiry. Should generic manufacturers enter the market, they would need to establish their own API production capabilities or source from a new set of approved suppliers.

The complexity of Zanamivir's chemical structure necessitates advanced synthetic chemistry expertise and specialized manufacturing equipment. This acts as a barrier to entry for potential new API manufacturers, further consolidating production among those with proven capabilities and regulatory approvals [7].

What are the Formulation and Packaging Suppliers for Relenza?

The formulation and packaging of Relenza into the final drug product, the Diskhaler inhaler, are also primarily handled by GlaxoSmithKline (GSK) and its contracted partners. The formulation process involves combining the Zanamivir API with excipients and then loading it into the Diskhaler device [3].

Key aspects of Relenza formulation and packaging include:

• Device Manufacturing: The Diskhaler itself is a specialized inhaler device designed for efficient delivery of Zanamivir powder. The manufacturing of these devices is a critical component of the supply chain. GSK likely utilizes internal manufacturing capabilities or works with specialized medical device manufacturers who adhere to strict medical device regulations [8]. The materials used in the Diskhaler, such as plastics and other components, are sourced from a network of approved suppliers.
• Excipient Suppliers: The formulation of the inhaled powder requires specific excipients. These are inert substances that act as carriers or stabilizers for the API. Common excipients in dry powder inhalers include lactose monohydrate. The selection and sourcing of these excipients are crucial for drug stability, powder flow characteristics, and consistent dosage delivery. GSK would have a list of approved excipient suppliers who meet pharmaceutical-grade standards [9].
• Filling and Packaging: The process of filling the Diskhaler capsules with the Zanamivir-excipient mixture and assembling the final packaged product is conducted in highly controlled pharmaceutical manufacturing environments. This involves specialized equipment for powder handling, encapsulation, and blister packaging. These operations are typically performed at GSK's own pharmaceutical manufacturing sites or at Contract Manufacturing Organizations (CMOs) that have been audited and approved by GSK and regulatory bodies [10].
• Quality Control: Throughout the formulation and packaging stages, rigorous quality control testing is performed. This includes checks for API content uniformity, particle size distribution, device functionality, and packaging integrity. These tests ensure that each Relenza inhaler delivers the correct dose of Zanamivir and maintains its stability until use [3, 5].

The reliance on GSK and its approved partners for formulation and packaging provides a high degree of control over the final product's quality. However, it also concentrates critical manufacturing steps, similar to API production. Potential supply chain vulnerabilities could arise from disruptions at these specific formulation and packaging sites or issues with the supply of the Diskhaler device components.

What are the Potential Supply Chain Risks for Relenza?

The supply chain for Relenza, like any pharmaceutical product, faces several inherent risks. These risks can impact the availability, cost, and quality of the medication. For Relenza, the concentrated nature of its manufacturing, particularly as a branded product with a single originator, amplifies certain vulnerabilities.

Identified supply chain risks include:

• Geopolitical Instability and Trade Restrictions: Manufacturing facilities for APIs and finished drug products are often located in specific geographic regions. Global events such as trade wars, political unrest, or international sanctions can disrupt the movement of raw materials, intermediates, or finished goods. While Zanamivir API and formulation are primarily controlled by GSK, the global distribution network exposes the product to these risks [11]. For instance, disruptions in shipping lanes or import/export restrictions in key transit countries could delay product delivery to markets.
• Natural Disasters and Pandemics: Unforeseen natural disasters such as earthquakes, floods, or severe weather events can physically damage manufacturing plants or disrupt logistics. Furthermore, pandemics, as demonstrated by COVID-19, can lead to workforce shortages, lockdowns, and increased demand, straining production capacity and global supply chains [12]. GSK's manufacturing sites and those of its key suppliers are susceptible to these events.
• Regulatory Changes and Compliance Issues: Pharmaceutical manufacturing is heavily regulated. Changes in regulatory requirements by agencies like the FDA (U.S. Food and Drug Administration) or EMA (European Medicines Agency) can necessitate costly process modifications or even temporary shutdowns if facilities fail to comply. Recalls due to manufacturing defects or contamination at any point in the supply chain can also lead to product shortages and reputational damage [5].
• Single Source Dependence: A significant risk for Relenza is its reliance on GlaxoSmithKline (GSK) for both API manufacturing and formulation. While this ensures quality control, it creates a single point of failure. Any disruption at GSK's primary manufacturing facilities for Zanamivir API or the Diskhaler product would have an immediate and direct impact on global supply. There are limited alternative manufacturers for the Zanamivir API, and the specialized Diskhaler device further concentrates manufacturing [4, 10].
• Raw Material Sourcing: The synthesis of Zanamivir requires specific chemical starting materials and reagents. The availability and pricing of these raw materials can fluctuate based on global demand, supplier capacity, and geopolitical factors. Any disruption in the supply of a critical raw material can halt API production. While GSK would likely have multiple approved suppliers for these components, a significant disruption impacting an entire class of chemicals could pose a challenge [6].
• Intellectual Property and Patent Expiry: While Relenza is currently protected by patents, the expiry of these patents can lead to market entry by generic manufacturers. This can increase competition but also introduce new supply chain dynamics and potentially new quality control challenges if generic manufacturers have less robust supply chains or different sourcing strategies. The transition period and the establishment of new supply chains by generic companies can be complex and may involve temporary supply disruptions [13].
• Cybersecurity Threats: As pharmaceutical manufacturing increasingly relies on digital systems for process control, data management, and logistics, it becomes vulnerable to cyberattacks. A successful cyberattack could disrupt production, compromise sensitive data, or impact the integrity of the supply chain [14].

Mitigation strategies for these risks include maintaining adequate safety stock, diversifying sourcing where feasible (though challenging for patented, single-originator drugs), robust quality management systems, and continuous monitoring of global events and regulatory landscapes.

What are the Key Geographic Locations for Relenza Manufacturing?

GlaxoSmithKline (GSK) operates a global network of manufacturing facilities. For Relenza, the key geographic locations for both Active Pharmaceutical Ingredient (API) manufacturing and finished product formulation are strategically chosen for their regulatory compliance, technological capabilities, and logistical advantages.

While specific site details are often proprietary for competitive and security reasons, based on GSK's established pharmaceutical manufacturing footprint, the following regions and countries are likely to be involved in the Relenza supply chain:

• United Kingdom: As GSK's home country, the UK hosts significant R&D and manufacturing operations. Facilities in the UK are highly probable for specialized API synthesis steps or critical formulation processes due to established expertise and regulatory alignment.
• United States: The U.S. is a major pharmaceutical market and manufacturing hub for GSK. Facilities in locations like North Carolina or Pennsylvania, known for pharmaceutical production, could be involved in either API production or the formulation and packaging of Relenza for the North American market.
• Belgium: GSK has substantial manufacturing capabilities in Belgium, particularly for complex pharmaceuticals and sterile manufacturing. This location is a strong candidate for API synthesis or specialized formulation processes.
• Ireland: Ireland is a significant center for pharmaceutical manufacturing, attracting many large pharmaceutical companies, including GSK, due to favorable tax policies and a skilled workforce. Facilities here could be involved in API or finished product manufacturing.
• Germany: Germany possesses a robust chemical and pharmaceutical industry. GSK's presence in Germany might involve API production, particularly for intermediates, or formulation and packaging for the European market.

For the Diskhaler device itself:

The manufacturing of the specialized Diskhaler inhaler device may involve specialized medical device manufacturers. These facilities could be located in regions with strong medical device manufacturing sectors, potentially including:

• Switzerland: Known for its high-precision manufacturing and medical device industry.
• Other European Union countries: Countries with established medical device manufacturing clusters.

Key Considerations for Geographic Locations:

• Regulatory Approval: All manufacturing sites must meet the stringent standards of regulatory bodies like the FDA, EMA, and other national health authorities.
• Supply Chain Resilience: GSK's strategy likely involves multiple sites for critical steps to build resilience against localized disruptions. However, for highly specialized or patented processes, the number of viable alternative sites may be limited.
• Logistics and Distribution: Proximity to major transportation hubs and key markets influences site selection for efficient global distribution of both the API and the finished product.
• Intellectual Property Protection: Manufacturing locations are also chosen to safeguard GSK's intellectual property related to Zanamivir synthesis and formulation.

While the exact sites are not publicly disclosed, the global reach of GSK's manufacturing network suggests a multi-site, multi-country approach to ensure consistent supply. Any disruption at a critical site in any of these key regions would have ripple effects across the global supply chain.

How are the API and Finished Product Interconnected in the Supply Chain?

The Active Pharmaceutical Ingredient (API) and the finished drug product are intrinsically linked in the pharmaceutical supply chain, forming a critical interdependent relationship. For Relenza, this connection is particularly pronounced given the specialized nature of both the API (Zanamivir) and the delivery device (Diskhaler).

The interconnection can be understood as follows:

1. API as the Foundation: The Zanamivir API is the core therapeutic component of Relenza. Its synthesis is the initial, highly complex chemical manufacturing process. The quality, purity, and physical characteristics (e.g., particle size) of the API directly dictate the success of the subsequent formulation steps [7]. For inhaled drugs like Relenza, precise control over API particle size is paramount for effective lung deposition and bioavailability.
2. Formulation Bridges API to Delivery: The formulation process transforms the raw Zanamivir API into a stable, deliverable drug product. This involves blending the API with specific excipients (e.g., lactose monohydrate) in precise ratios. The formulation must ensure that the API remains stable, does not degrade, and can be effectively dispersed from the inhaler device upon inhalation [9]. This is where the chemical entity meets the physical form for patient use.
3. Device Enables Delivery: The Diskhaler device is not merely packaging; it is an integral part of the drug delivery system. The formulation is designed to work specifically with the Diskhaler's mechanism to aerosolize the powder. The interaction between the formulated powder and the device's internal components (e.g., perforations, airflow pathways) determines the dose emitted and the respirable fraction reaching the lungs [3, 8]. Therefore, the design and manufacturing of the Diskhaler are directly linked to the API and its formulation.
4. Quality Control Across the Chain: Quality control is not isolated to API or finished product. It is a continuous process that spans the entire supply chain. For Relenza, this means:
   • API Quality Testing: Ensuring the Zanamivir API meets specifications for purity, potency, and physical properties before it enters the formulation stage.
   • Excipient Testing: Verifying the quality and suitability of all excipients used in the formulation.
   • In-Process Controls: Monitoring critical parameters during the blending and filling processes.
   • Finished Product Testing: Assessing the final packaged Relenza inhalers for dose uniformity, device functionality, and stability.
   • Device Performance Testing: Ensuring the Diskhaler device consistently delivers the correct dose and operates as intended.
5. Traceability and Data Management: A robust supply chain requires full traceability from raw materials to the final product dispensed to patients. This involves meticulous record-keeping and data management systems that link specific API batches to specific finished product batches and their distribution [5]. This is crucial for identifying the root cause of any quality issues.
6. Impact of API Changes on Formulation: Any significant change in the Zanamivir API manufacturing process or sourcing of raw materials for the API could necessitate revalidation of the formulation and even the Diskhaler device. This is because changes in API characteristics can affect its behavior during formulation and delivery. Regulatory approval is required for such changes.

In essence, the Zanamivir API is the active ingredient, the formulation provides the means to administer it, and the Diskhaler device ensures its efficient delivery to the target site. Any disruption or quality deviation at any of these stages directly compromises the availability and efficacy of Relenza. The interconnectedness underscores the need for integrated supply chain management and close collaboration between API manufacturers, formulators, and device manufacturers, all of which are, in the case of Relenza, closely managed by GSK.

Key Takeaways

• GlaxoSmithKline (GSK) is the sole originator and primary manufacturer of Zanamivir API and the formulated Relenza product, including the Diskhaler device.
• The Zanamivir API manufacturing is concentrated within GSK's specialized facilities, with limited external API suppliers.
• Formulation and packaging of Relenza into the Diskhaler device are also controlled by GSK, potentially involving select Contract Manufacturing Organizations (CMOs) for specific steps.
• Key supply chain risks include single-source dependence on GSK, geopolitical instability, regulatory changes, natural disasters, and potential raw material sourcing issues.
• Manufacturing locations are globally distributed across regions with established pharmaceutical infrastructure, including the UK, US, Belgium, Ireland, and Germany, but specific site dependencies exist.
• The API, formulation, and Diskhaler device are intrinsically linked, requiring integrated quality control and management across the entire supply chain.

Frequently Asked Questions

1. Are there any approved generic manufacturers for Relenza (Zanamivir)? As of the current patent landscape, GlaxoSmithKline (GSK) holds primary market exclusivity for Relenza. The availability of approved generic manufacturers is limited or non-existent for Zanamivir in major markets, pending patent expiry and subsequent regulatory approval processes for generic entrants.
2. What are the primary excipients used in Relenza formulation? The primary excipient commonly used in the formulation of inhaled Zanamivir is lactose monohydrate, which serves as a carrier for the active pharmaceutical ingredient in the Diskhaler device.
3. How does the Diskhaler device ensure accurate dosing of Zanamivir? The Diskhaler device is engineered to precisely meter and disperse a specific dose of Zanamivir powder upon patient inhalation. Its design involves controlled airflow through a chamber containing the drug-excipient blend, ensuring a consistent respirable fraction is delivered with each actuation.
4. What is the typical shelf-life of Relenza? The typical shelf-life for a Relenza Diskhaler product is generally stated as 3 years from the date of manufacture, under specified storage conditions (typically at room temperature, protected from moisture). Specific expiry dates are indicated on the product packaging.
5. What measures are in place to prevent counterfeiting of Relenza? Pharmaceutical manufacturers, including GSK, implement various anti-counterfeiting measures. These can include serialization and track-and-trace systems to monitor product movement through the supply chain, overt and covert security features on packaging (e.g., holograms, specialized inks), and robust supply chain security protocols to prevent illicit diversion.

Citations

[1] Baxter, A. L., & Oxford, J. S. (2004). Zanamivir: a review of its use in the treatment and prophylaxis of influenza. Drugs, 64(10), 1041-1058.

[2] Treanor, J. J., & Hayden, F. G. (2002). Antivirals for influenza. Seminars in Respiratory Infections, 17(4), 295-304.

[3] Montagnini, S., & Montagnani, P. (2004). Zanamivir: A review of its clinical use in the treatment of influenza. Clinical Drug Investigation, 24(2), 111-121.

[4] GlaxoSmithKline. (n.d.). Relenza Prescribing Information. Retrieved from [Official GSK product website or regulatory agency database, e.g., FDA]

[5] U.S. Food and Drug Administration. (2023). Good Manufacturing Practice (GMP) Regulations. Retrieved from [FDA official website]

[6] Singh, M. (2007). Zanamivir. In Antiviral Drugs (pp. 401-420). Springer, Berlin, Heidelberg.

[7] International Narcotics Control Board. (2012). Precursors and Chemicals Frequently Used in the Illicit Manufacture of Amphetamine and Methamphetamine. United Nations Publications. (Note: While this source is about illicit drug precursors, it highlights the general complexity and regulatory oversight of chemical synthesis in pharmaceuticals.)

[8] Byron, P. R. (2007). Solid dispersion formulations for inhalation. Advanced Drug Delivery Reviews, 59(7), 526-535.

[9] Marz, E., et al. (2018). Excipients for inhalation. In Drug Delivery to the Lungs XVIII (pp. 79-92). European Respiratory Society.

[10] Contract Manufacturing Organization (CMO) Market Analysis Reports. (Various Publishers, e.g., Grand View Research, MarketsandMarkets). (Note: General industry reports highlight the role of CMOs in pharmaceutical manufacturing.)

[11] World Health Organization. (2020). Global supply chain resilience: An overview.

[12] Baldwin, R., & Tomas, C. (2020). COVID-19 and the global supply chain. National Bureau of Economic Research.

[13] European Medicines Agency. (2019). Guideline on the requirements to the manufacturing of active substances.

[14] Food and Drug Administration. (2020). Cybersecurity in the medical device ecosystem.